ArticleWorld journal of otorhinolaryngology - head and neck surgery2025
The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real-Life Multicenter Study by a Tuscany Group.
Article in World journal of otorhinolaryngology - head and neck surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type-2 diseases. Dupilumab, a monoclonal antibody targeting IL-4Rα, has revolutionized the treatment of severe CRSwNP. Traditionally, intranasal corticosteroids (INCS) are used in association with Dupilumab, but their necessity remains uncertain. Methods: This real-life, multicentric observational study was conducted across seven centers in Tuscany, Italy, involving 123 patients with severe, uncontrolled type-2 CRSwNP treated with Dupilumab (300 mg/2 weeks) from January 2021 to December 2022. Parameters assessed included Sinonasal Outcome Test-22 (SNOT-22), Nasal Polyps Score (NPS), Sniffin' Sticks identification test (SSIT-16), and Lund-Mackay scores (LMS), along with blood eosinophil counts and adherence to INCS. Statistical analyses were performed to compare outcomes between INCS adherent and non-adherent groups. Results: A total of 123 patients, 53 men and 70 women with a mean age of 56.6 years were included. Significant improvements were observed in SNOT-22, NPS, SSIT, and LMS over 12 months. INCS adherence was incomplete in 23.8% of patients. Initially, non-adherent patients demonstrated a faster SNOT-22 reduction, while adherent patients showed better NPS and SSIT improvements early on. By 12 months, differences between groups were not statistically significant. No demographic or clinical factors predicted INCS adherence. Conclusion: Dupilumab is effective in managing type-2 CRSwNP, potentially without INCS. While INCS may hasten initial improvements, long-term outcomes are comparable with or without their use. Future randomized controlled trials are necessary to further clarify INCS's role in combination with Dupilumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.